Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn

Table of Contents

March 01, 2004; Volume 32,Issue 3

Symposium Article

  • You have access
    GLUCURONIDATION AND THE UDP-GLUCURONOSYLTRANSFERASES IN HEALTH AND DISEASE
    Peter G. Wells, Peter I. Mackenzie, Jayanta Roy Chowdhury, Chantal Guillemette, Philip A. Gregory, Yuji Ishii, Antony J. Hansen, Fay K. Kessler, Perry M. Kim, Namita Roy Chowdhury and Joseph K. Ritter
    Drug Metabolism and Disposition March 2004, 32 (3) 281-290; DOI: https://doi.org/10.1124/dmd.32.3.281

Short Communication

  • You have access
    INVOLVEMENT OF ORGANIC ANION TRANSPORTING POLYPEPTIDES IN THE TRANSPORT OF TROGLITAZONE SULFATE: IMPLICATIONS FOR UNDERSTANDING TROGLITAZONE HEPATOTOXICITY
    Takashi Nozawa, Shigeki Sugiura, Miki Nakajima, Akihiko Goto, Tsuyoshi Yokoi, Jun-Ichi Nezu, Akira Tsuji and Ikumi Tamai
    Drug Metabolism and Disposition March 2004, 32 (3) 291-294; DOI: https://doi.org/10.1124/dmd.32.3.291

Articles

  • You have access
    IMPACT OF INCUBATION CONDITIONS ON BUFURALOL HUMAN CLEARANCE PREDICTIONS: ENZYME LABILITY AND NONSPECIFIC BINDING
    Robert S. Foti and Michael B. Fisher
    Drug Metabolism and Disposition March 2004, 32 (3) 295-304; DOI: https://doi.org/10.1124/dmd.32.3.295
  • You have access
    STEREO- AND REGIOSELECTIVITY ACCOUNT FOR THE DIVERSITY OF DEHYDROEPIANDROSTERONE (DHEA) METABOLITES PRODUCED BY LIVER MICROSOMAL CYTOCHROMES P450
    Kristy K. Michael Miller, Jian Cai, Sharon L. Ripp, William M. Pierce, Thomas H. Rushmore and Russell A. Prough
    Drug Metabolism and Disposition March 2004, 32 (3) 305-313; DOI: https://doi.org/10.1124/dmd.32.3.305
  • You have access
    IDENTIFICATION OF HUMAN UDP-GLUCURONOSYLTRANSFERASE ENZYME(S) RESPONSIBLE FOR THE GLUCURONIDATION OF EZETIMIBE (ZETIA)
    Anima Ghosal, Neil Hapangama, Yuan Yuan, Joana Achanfuo-Yeboah, Robert Iannucci, Swapan Chowdhury, Kevin Alton, James E. Patrick and Shmuel Zbaida
    Drug Metabolism and Disposition March 2004, 32 (3) 314-320; DOI: https://doi.org/10.1124/dmd.32.3.314
  • You have access
    CYTOTOXICITY OF THE NOVEL GLUTATHIONE-ACTIVATED THIOPURINE PRODRUGS CIS-AVTP [CIS-6-(2-ACETYLVINYLTHIO)PURINE] AND TRANS-AVTG [TRANS-6-(2-ACETYLVINYLTHIO)GUANINE] RESULTS FROM THE NATIONAL CANCER INSTITUTE'S ANTICANCER DRUG SCREEN
    Sjofn Gunnarsdottir and Adnan A. Elfarra
    Drug Metabolism and Disposition March 2004, 32 (3) 321-327; DOI: https://doi.org/10.1124/dmd.32.3.321
  • You have access
    AN ANALYSIS OF THE REGIOSELECTIVITY OF AROMATIC HYDROXYLATION AND N-OXYGENATION BY CYTOCHROME P450 ENZYMES
    Tamara S. Dowers, Dan A. Rock, Denise A. Rock, Brandon N. S. Perkins and Jeffery P. Jones
    Drug Metabolism and Disposition March 2004, 32 (3) 328-332; DOI: https://doi.org/10.1124/dmd.32.3.328
  • You have access
    IN VITRO SULFOXIDATION OF THIOETHER COMPOUNDS BY HUMAN CYTOCHROME P450 AND FLAVIN-CONTAINING MONOOXYGENASE ISOFORMS WITH PARTICULAR REFERENCE TO THE CYP2C SUBFAMILY
    Khawja A. Usmani, Edward D. Karoly, Ernest Hodgson and Randy L. Rose
    Drug Metabolism and Disposition March 2004, 32 (3) 333-339; DOI: https://doi.org/10.1124/dmd.32.3.333
  • You have access
    HUMAN PXR VARIANTS AND THEIR DIFFERENTIAL EFFECTS ON THE REGULATION OF HUMAN UDP-GLUCURONOSYLTRANSFERASE GENE EXPRESSION
    Dione Gardner-Stephen, Jean-Marie Heydel, Amit Goyal, Yuan Lu, Wen Xie, Tim Lindblom, Peter Mackenzie and Anna Radominska-Pandya
    Drug Metabolism and Disposition March 2004, 32 (3) 340-347; DOI: https://doi.org/10.1124/dmd.32.3.340
  • You have access
    REGULATION OF CYP2B6 IN PRIMARY HUMAN HEPATOCYTES BY PROTOTYPICAL INDUCERS
    Stephanie R. Faucette, Hongbing Wang, Geraldine A. Hamilton, Summer L. Jolley, Darryl Gilbert, Celeste Lindley, Bingfang Yan, Masahiko Negishi and Edward L. LeCluyse
    Drug Metabolism and Disposition March 2004, 32 (3) 348-358; DOI: https://doi.org/10.1124/dmd.32.3.348

Accelerated Communication

  • You have access
    KUPFFER CELL-MEDIATED IL-2 SUPPRESSION OF CYP3A ACTIVITY IN HUMAN HEPATOCYTES
    Jeffrey A. Sunman, Roy L. Hawke, Edward L. LeCluyse and Angela D. M. Kashuba
    Drug Metabolism and Disposition March 2004, 32 (3) 359-363; DOI: https://doi.org/10.1124/dmd.32.3.359

Letter to the Editor

  • You have access
    IS 17α-ETHINYL ESTRADIOL AN INHIBITOR OF CYTOCHROME P450 2C19?
    A. David Rodrigues and Ping Lu
    Drug Metabolism and Disposition March 2004, 32 (3) 364-365; DOI: https://doi.org/10.1124/dmd.32.3.364

Erratum

  • You have access
    CORRECTION TO “STUDIES ON THE METABOLISM OF THE NOVEL, SELECTIVE CYCLOOXYGENASE-2 INHIBITOR INDOMETHACIN PHENETHYLAMIDE IN RAT, MOUSE, AND HUMAN LIVER MICROSOMES: IDENTIFICATION OF ACTIVE METABOLITES”
    Drug Metabolism and Disposition March 2004, 32 (3) 366; DOI: https://doi.org/10.1124/dmd.32.3.366
Back to top
PreviousNext

In this issue

Drug Metabolism and Disposition: 32 (3)
Drug Metabolism and Disposition
Vol. 32, Issue 3
1 Mar 2004
  • Table of Contents
  • About the Cover
  • Index by author
Sign up for alerts

Jump to

  • Symposium Article
  • Short Communication
  • Articles
  • Accelerated Communication
  • Letter to the Editor
  • Erratum
  • Most Cited
  • Most Read
Loading
  • Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes.
  • Prediction of Human Clearance of Twenty-Nine Drugs from Hepatic Microsomal Intrinsic Clearance Data: An Examination of In Vitro Half-Life Approach and Nonspecific Binding to Microsomes
  • DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS
  • In Vitro-In Vivo Scaling of CYP Kinetic Data Not Consistent with the Classical Michaelis-Menten Model
  • THE HUMAN INTESTINAL CYTOCHROME P450 “PIE”
More...
Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics